Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…Purpose<p>CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.…”

Effect of different doses of the defatted extract (DE) of the leaves of <i>S. malaccense</i> and <i>S. samarangense</i> on urea and creatinine levels. Data represented as mean±SEM... by Fatma A. Moharram (9276104)

Subjects:

The results of linear mixed model. by Soheila Qanbari (20455173)

Subjects:

The flow of the participants from enrollment to analysis. by Soheila Qanbari (20455173)

Subjects:

Correlation between treatment-induced changes in lumbar motor control and N150 amplitude. by Soheila Qanbari (20455173)

Subjects:

Sensory-evoked potentials of N80 and N150. by Soheila Qanbari (20455173)

Subjects:

The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

Subjects:

Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data. by Soheila Qanbari (20455173)

Subjects:

The demographical and clinical characteristics of subjects at baseline. by Soheila Qanbari (20455173)

Subjects:

Electrode montage and electric field distribution simulated with SimNIBS software. by Soheila Qanbari (20455173)

Subjects:

Particle size distribution of GO-GA NPs. by Huda H. Elbehery (22492996)

Subjects:

Fourier-transform infrared spectroscopy (FTIR) spectra of GA (black), GO (blue), and GO–GA NPs (red). by Huda H. Elbehery (22492996)

Subjects:

Toxicity of GO and GO-GA NPs on <i>C. maculatus</i> adults after 24h exposure. by Huda H. Elbehery (22492996)

Subjects:

Mean persistence (±SE) of GO and GO-GA NPs on <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Subjects:

Post-effect of GO and GO-GA NPs on progeny production of <i>Callosobruchus maculatus.</i> by Huda H. Elbehery (22492996)

Subjects:

Transmission electron micrographs of GA NPs (a) and GO-GA NPs (b). by Huda H. Elbehery (22492996)

Subjects:

Particle size distribution, PDI, and zeta potential of GO-GA NPs. by Huda H. Elbehery (22492996)

Subjects: